Chemotherapy for metastatic breast cancer-report of a European expert panel.
暂无分享,去创建一个
M. Piccart | J. Crown | G. von Minckwitz | S. Kaye | V. Diéras | M. Kaufmann | M. Marty | J. Misset | B. Osterwalder | R. Leonard
[1] C. Seynaeve,et al. Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane , 2001, Breast Cancer Research and Treatment.
[2] I. Tannock,et al. Third line chemotherapy in patients with metastatic breast cancer: an evaluation of quality of life and cost , 1999, Breast Cancer Research and Treatment.
[3] David Miles,et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Blackstein,et al. Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II Trial , 2002, Oncology.
[5] G. Peters,et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. , 2002, European journal of cancer.
[6] L. Zelek,et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma , 2001, Cancer.
[7] A. Buzdar,et al. Multicenter, Phase II study of capecitabine in taxane‐pretreated metastatic breast carcinoma patients , 2001, Cancer.
[8] L. Zelek,et al. Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanes. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] A. Buzdar,et al. Capecitabine (Xeloda) in 162 patients with paclitaxel-pretreated mbc: updated results and analysis of dose modification , 2001 .
[10] S. Frings,et al. Capecitabine: The new standard in metastatic breast cancer failing anthracycline and taxane-containing chemotherapy? Mature results of a large multicenter phase II trial , 2001 .
[11] V. Lorusso,et al. Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] L. Balducci. Geriatric oncology: challenges for the new century. , 2000, European journal of cancer.
[13] D. Crivellari,et al. Combination chemotherapy with navelbine and continuous infusion of 5-fluorouracil in metastatic, chemotherapy refractory breast cancer. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] G. Pacilio,et al. A Phase II Study of Paclitaxel/Cisplatin Combination in Patients with Metastatic Breast Cancer Refractory to Anthracycline-Based Chemotherapy , 2000, Tumori.
[15] V. Gebbia,et al. Gemcitabine and vinorelbine in pretreated advanced breast cancer: a pilot study. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] J. Klijn,et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Bonneterre,et al. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] L. Zelek,et al. Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] K. Friedrichs,et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] A. Irvine,et al. Infusional 5-fluorouracil can be a pain in the neck: A case for repositioning displaced Hickman lines. , 1999, Clinical oncology (Royal College of Radiologists (Great Britain)).
[21] J. Bergh,et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. , 1999, European journal of cancer.
[22] O. Sezer,et al. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. , 1999, Anti-cancer drugs.
[23] P. Prandoni,et al. Upper extremity deep vein thrombosis. , 1999, Current opinion in pulmonary medicine.
[24] D. Richel,et al. Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy , 1999 .
[25] B. Dörken,et al. Brain metastases in breast cancer: prognostic factors and management. , 1999, European journal of cancer.
[26] E. Salminen,et al. Docetaxel: standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] A. Buzdar,et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] V Torri,et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] G. Hortobagyi,et al. Treatment of breast cancer. , 1998, The New England journal of medicine.
[30] G. Hortobagyi,et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Mike Clarke,et al. Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[32] D. Tu,et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] M. Ratain,et al. Oral chemotherapy: rationale and future directions. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] R. Coombes,et al. Docetaxel: response in patients who have received at least two prior chemotherapy regimens for metastatic breast cancer. , 1998, European journal of cancer.
[35] R. Carlson. Quality of life issues in the treatment of metastatic breast cancer. , 1998, Oncology.
[36] J. Blay,et al. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline‐ and/or paclitaxel‐containing regimens , 1998, Cancer.
[37] C. Topham,et al. Patient preferences for chemotherapy schedules used in the treatment of advanced colorectal cancer--a pilot study. , 1997, European journal of cancer care.
[38] M. Sabel,et al. Principles of chronic venous access: recommendations based on the Roswell Park experience. , 1997, Surgical oncology.
[39] M. Colleoni,et al. Mitomycin C and Vinorelbine in Pretreated Breast Cancer , 1997, Tumori.
[40] R. Livingston,et al. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] A. Norman,et al. A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy. , 1997, European journal of cancer.
[42] E. Warner,et al. Patient preferences for oral versus intravenous palliative chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] W. Bemelman,et al. Complications of an implantable venous access device (Port-a-Cath) during intermittent continuous infusion of chemotherapy. , 1996, European journal of cancer.
[44] G. Hortobagyi,et al. Current management of advanced breast cancer. , 1996, Seminars in oncology.
[45] R. Lowenthal,et al. Home chemotherapy for cancer patients: cost analysis and safety , 1996, The Medical journal of Australia.
[46] L. Norton,et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] P. Fumoleau,et al. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] A. Vincent-Salomon,et al. Meningeal carcinomatosis in patients with breast carcinoma: Clinical features, prognostic factors, and results of a high‐dose intrathecal methotrexate regimen , 1996, Cancer.
[49] C. Dittrich,et al. Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel – a phase II study , 1996, Cancer Chemotherapy and Pharmacology.
[50] A. Harris,et al. Advanced breast cancer: a phase II trial with gemcitabine. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] P. Schweitzer,et al. Radiation therapy-induced cardiac injury. , 1995, American heart journal.
[52] P. Lønning,et al. Treatment of relapse of breast cancer after adjuvant systemic therapy--review and guidelines for future research. , 1994, European journal of cancer.
[53] S. Ebbs,et al. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. , 1993, British Journal of Cancer.
[54] S. Payne. A study of quality of life in cancer patients receiving palliative chemotherapy. , 1992, Social science & medicine.
[55] M. F. Chen,et al. Heart diseases following radiotherapy. , 1991, Journal of the Formosan Medical Association = Taiwan yi zhi.
[56] I. Henderson,et al. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] A. Howell,et al. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. , 1988, European journal of cancer & clinical oncology.
[58] J. Doroshow,et al. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] Yoshiaki Tsukada,et al. Central nervous system metastasis from breast carcinoma autopsy study , 1983, Cancer.